MedTrace Logo

Early Detection of COPD Patients in GOLD 0 (Smokers) Population

NCT01550679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-12-29

No results posted yet for this study

Summary

Even though the main risk factor for the development of chronic obstructive pulmonary disease (COPD) is smoking only in less than one third of the smokers the clinically manifest COPD will develop. The disease progressive nature with high disability and mortality especially in the final stages makes it plausible to detect the disease as early as possible thus allowing for the early intervention. Major intervention trials in COPD, "Towards a Revolution in COPD Health" (TORCH), "Investigating New Standards for Prophylaxis in Reducing Exacerbations" (INSPIRE), and "Understanding Potential Long-term Impacts on Function with Tiotropium" (UPLIFT) have recently shown that the beneficial impact of intervention was larger in patients being treated in earlier stages of the disease development. Till now the only tool for an early diagnosis and early intervention that could be used on the global scale was spirometry even though symptoms and deprivation of quality of life (QoL) precedes clinically relevant spirometric changes. So there is a need for a new simple tool that would allow detection of patients in a very early stage of COPD.

So the aim of this study is the development of diagnostic tools for an early detection of COPD, even before the significant change in spirometry.

Conditions

  • COPD
  • Smoking
  • Other Diagnoses, Comorbidities, and Complications

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University Hospital Rijeka

    collaborator OTHER

  • Clinical Hospital Center, Split

    collaborator OTHER

  • General Hospital Dubrovnik

    collaborator OTHER

  • Institute for Medical Research and Occupational Health, Zagreb

    collaborator UNKNOWN

  • Osijek University Hospital

    collaborator OTHER

  • Children's Hospital Srebrnjak

    lead OTHER

Principal Investigators

  • Davor Plavec, MD, PhD · Children's Hospital Srebrnjak

  • Žarko Vrbica, MD, MSc · General Hospital Dubrovnik

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01550679 on ClinicalTrials.gov